Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Forum Sponsorship (as of December 31, 2013) Financial support for the Forum is derived from private foundations, government agencies, industry sponsors, and nonprofit associations. Private Foundations Burroughs Wellcome Fund CDC Foundation Doris Duke Charitable Foundation Eli Lilly & Co. Foundation Fondation Mérieux Other Nonprofit Organizations American Diabetes Association American Society for Microbiology Association of American Medical Colleges Critical Path Institute FasterCures Friends of Cancer Research March of Dimes Foundation Government Sponsors Food and Drug Administration National Cancer Institute (NIH) National Center for Advancing Translational Sciences (NIH) National Institute of Allergy and Infectious Diseases (NIH) National Institute of Mental Health (NIH) National Institute of Neurological Disorders and Stroke (NIH) Industry Sponsors AbbVie Inc. Amgen Inc. AstraZeneca Eli Lilly & Co. GlaxoSmithKline Johnson & Johnson Merck & Co. Novartis Pharmaceuticals Corporation Pfizer Inc. Sanofi May 12 Workshop: Characterizing and Communicating October 7â8 Uncertainty in the Assessment of Benefits and Forum Meeting #29 Risks of Pharmaceutical Products (Day 2) 2015 June 10â11 Forum Meeting #28
Forum Members Forum Sponsorship and Membership (as of December 31, 2013) Membership in the Forum includes a diverse range of stakeholders from multiple sectors, including government, the pharmaceutical and biotechnology industries, biomedical research funders and sponsors, academia, and patient groups. Jeffrey Drazen (Co-Chair) Kathy Hudson Robert Ratner New England Journal of Medicine National Institutes of Health American Diabetes Association Steven Galson (Co-Chair) Lynn Hudson Michael Rosenblatt Amgen Inc. Critical Path Institute Merck & Co., Inc. Russ Altman S. Claiborne (Clay) Johnston James Shannon Stanford University University of California, San GlaxoSmithKline Margaret Anderson Francisco Janet Shoemaker FasterCures Michael Katz American Society for Microbiology Hugh Auchincloss March of Dimes Foundation Ellen Sigal National Institute of Allergy and Petra Kaufmann Friends of Cancer Research Infectious Diseases National Institute of Neurological Lana Skirboll Christopher Austin Disorders and Stroke Sanofi National Center for Advancing Jack Keene Brian Strom Translational Sciences Duke University Medical Center Rutgers, the State University of New Ann Bonham Rusty Kelley Jersey Association of American Medical Burroughs Wellcome Fund Janet Tobias Colleges Ronald Krall Ikana Health Linda Brady University of Pennsylvania Joanne Waldstreicher National Institute of Mental Health Freda Lewis-Hall Johnson & Johnson Gail Cassell Pfizer Inc. Janet Woodcock Harvard Medical School Department Carol Mimura FDA Center for Drug Evaluation and of Social and Global Medicine University of California, Berkeley Research (Visiting) Bernard Munos Andrew Dahlem InnoThink Center for Research in Eli Lilly & Co. Biomedical Innovation Membership James Doroshow Elizabeth (Betsy) Myers National Cancer Institute Doris Duke Charitable Foundation Patient Gary Filerman Advocacy John Orloff Government Atlas Health Foundation Novartis Pharmaceuticals 11% Mark Goldberger Corporation Foundations and 18% AbbVie Inc. Associations 11% Harry Greenberg Stanford University School of Biotech/Other 5% Medicine Industry 18% Academia Peter Honig AstraZeneca 24% 13% Pharma Miscellaneous Non-Profit
About the Forum on Drug Discovery, Development, and Translation About the Institute of Medicine The IOMâs Forum on Drug Discovery, Development, and Translation The Institute of Medicine was established was created in 2005 by the IOMâs Board on Health Sciences Policy in 1970 by the National Academy of Sciences to provide a unique platform for dialogue and collaboration among to secure the services of eminent members of thought leaders and stakeholders in government, academia, industry, appropriate professions in the examination of foundations, and patient advocacy. The Forum brings together lead- policy matters pertaining to the health of the ers from private-sector sponsors of biomedical and clinical research, public. The Institute acts under the respon- federal agencies sponsoring and regulating biomedical and clinical sibility assigned to the National Academy of research, the academic community, and patients, and in doing so Sciences by its congressional charter to serve serves to educate the policy community about issues where science as an advisor to the federal government and policy intersect. and, upon its own initiative, to identify issues needing attention in the areas of medical The Forum convenes several times each year to identify and discuss care, research, and education. key problems and strategies in the discovery, development, and translation of drugs. To supplement the perspectives and expertise Forum Staff of its members, the Forum also holds public workshops to engage Anne B. Claiborne, J.D., M.P.H. a wide range of experts, members of the public, and the policy Forum Director community in discussing areas of concern in the science and policy Rebecca A. English, M.P.H. of drug development. The Forum also fosters collaborations among Program Officer its members and constituencies. The Forumâs public meetings focus Elizabeth F. C. Tyson substantial public attention on critical areas of drug development. Associate Program Officer Proceedings and speaker presentations are disseminated to the pub- Robin Guyse (until January 2014) lic though published summaries and the Forum website. For more Senior Program Assistant information about the Forum on Drug Discovery, Development, and Translation, please visit our website at www.iom.edu/drug. Barret Zimmermann (as of January 2014) Senior Program Assistant Board on Health Sciences Policy Andrew M. Pope, Ph.D. Director The Institute of Medicine serves as adviser to the nation to improve health. Established in 1970 under the charter of the National Academy of Sciences, the Institute of Medicine provides independent, objective, evidence-based advice to policymakers, health professionals, the private sector, and the public. The mission of the Institute of Medicine embraces the health of people everywhere.
